Stay updated on Empagliflozin Effect on Tissue Sodium in Heart Failure Clinical Trial
Sign up to get notified when there's something new on the Empagliflozin Effect on Tissue Sodium in Heart Failure Clinical Trial page.

Latest updates to the Empagliflozin Effect on Tissue Sodium in Heart Failure Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision label updated to v3.5.0 and previous revision v3.4.3 removed. This reflects a backend update to the page's versioning rather than changes to study data.SummaryDifference0.1%

- Check20 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedAdded the final published reference (Eur J Heart Fail, 2025) and removed the online-ahead-of-print citation for the study publications section.SummaryDifference0.1%

- Check49 days agoChange DetectedRevision: v3.4.2 was added. The long notice about government funding lapses and the previous Revision: v3.4.1 entry were removed.SummaryDifference0.5%

- Check56 days agoChange DetectedA site-wide notice about a lapse in government funding and the NIH Clinical Center's operating status was added, including links to cc.nih.gov and opm.gov. The page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check63 days agoChange DetectedAdded a glossary display option and a new QC-related label ('Last Update Submitted that Met QC Criteria'), updated FEAR Act labeling, and bumped the revision to v3.4.0. The previous QC label capitalization and version 3.3.4 were removed.SummaryDifference0.2%

Stay in the know with updates to Empagliflozin Effect on Tissue Sodium in Heart Failure Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Empagliflozin Effect on Tissue Sodium in Heart Failure Clinical Trial page.